Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Recruiting 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 49Breast Neoplasms 47Neoplasms 39Leukemia, Lymphocytic, Chronic, B-Cell 37Carcinoma, Non-Small-Cell Lung 36Neoplasm Metastasis 29Lymphoma, Large B-Cell, Diffuse 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Brain Neoplasms 24Lymphoma, Follicular 23Lung Neoplasms 23Colonic Neoplasms 23Rectal Neoplasms 22Carcinoma, Renal Cell 22Lymphoma, Non-Hodgkin 21Prostatic Neoplasms 20Glioblastoma 20Leukemia, Myeloid, Acute 19Kidney Neoplasms 19Pancreatic Neoplasms 18Lymphoma, B-Cell, Marginal Zone 18Lymphoma, Mantle-Cell 17Gliosarcoma 17Burkitt Lymphoma 17Sarcoma 16Multiple Myeloma 16Waldenstrom Macroglobulinemia 15Ovarian Neoplasms 15Esophageal Neoplasms 15Lymphoma 14

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NIH × Neoplastic Syndromes, Hereditary × Clear all
NCT02504892 2019-03-22

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
3 enrolled 7 charts
Genitourinary

Kidney Neoplasms, Neoplastic Syndromes, Hereditary, Birt-Hogg-Dube Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡